Surgery Partners (SGRY) Resets 2026 Outlook On Facility Removal As Valuation Questions Build

Surgery Partners (SGRY) updated its 2026 outlook, guiding revenue to a range of $3.08b to $3.18b. The revision reflects the removal of Idaho Falls Facilities’ contribution for the rest of the year.

The updated 2026 outlook lands as Surgery Partners’ share price has been under pressure, with the stock down 7.86% over the past week and 13.17% year to date on a share price return basis, while the 1-year total shareholder return has declined 38.71%. This points to fading momentum as investors reassess both growth prospects and risk.

Position your portfolio for where Surgery Partners' peers could move next by scanning our curated set of 16 high quality undiscovered gems, which share similar healthcare characteristics and have shown stronger recent share price trends.

After a sharp reset in both guidance and share price, Surgery Partners now sits at a crossroads. Does it make more sense to step in here, or to wait for an even cheaper valuation to show up in the numbers?

Most Popular Narrative: 26% Undervalued

On the most followed view of Surgery Partners, a fair value of about $17.95 sits well above the last close of $13.25. This frames the current weakness as a valuation gap rather than just a sentiment slump.

The accelerated migration of high-acuity surgical procedures (particularly orthopedics and joint replacements) from hospitals to outpatient settings is strengthening, with Surgery Partners demonstrating outperformance through investments in robotics and facility capabilities, positioning the company to capitalize on expanding case volumes and higher-revenue procedures directly supporting long-term revenue and EBITDA growth.

See why 5 investors see Surgery Partners as 26% undervalued.

Result: Fair Value of $17.95 (UNDERVALUED)

Still, rising interest expenses and anesthesia related cost pressures could keep earnings under strain and challenge the upbeat valuation narrative for Surgery Partners.

Find out about the key risks to this Surgery Partners narrative.

Next Steps

Sentiment in the Surgery Partners story is clearly mixed, so move quickly to check the underlying data and weigh it against the 4 key rewards

Looking for more Surgery Partners style investment ideas?

If Surgery Partners has sharpened your focus on quality opportunities, do not stop here. Use the Simply Wall Street Screener to uncover the next potential addition to your portfolio before others catch on.

• Target potential mispricings by hunting for quality companies that may trade below intrinsic value through the 33 high quality undervalued stocks.
• Build a sturdier portfolio by focusing on businesses with stronger finances using the list of solid balance sheet and fundamentals (23 results).
• Seek steadier compounding potential by scanning income focused ideas through the 6 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com